Lung Cancer’s Hidden Layers - Takeaway - MDSpire
Clinical Guidelines
Feature

Lung Cancer’s Hidden Layers

Study shows that tumor complexity can limit biopsy-based diagnosis

  • April 22, 2026

  • 2 min

Share

  • 1

    cSCLC represents 2-5% of small-cell lung cancer cases.

  • 2

    The diagnosis is usually based on surgical specimens.

  • 3

    Small biopsies may lead to underdiagnosis.

  • 4

    A new assay ('cSCLC Detector') improves sensitivity for cSCLC detection.

  • 5

    Tumor heterogeneity complicates accurate classification.

  • 6

    cSCLC tumors show spatial heterogeneity in components and microenvironments.

  • 7

    Evidence of tumor plasticity identified in mixed cellular states.

Original Source(s)

Lung Cancer’s Hidden Layers

  • April 22, 2026

Related Content

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker for angioimmunoblastic T-cell lymphoma, a rare subtype of non-H...

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed...

First-Line Zongertinib in Advanced <em>HER2</em>-Mutant NSCLC

In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell...